Scarica l'app Stockscreener
649.76
3.09%
19.46
Pre-mercato:
649.76
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron backed Parabilis Medicines seeks U.S. IPO - Seeking Alpha
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud - Business Wire
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets - Yahoo Finance
Tredje AP fonden Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Resona Asset Management Co. Ltd. Has $24.71 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ProShare Advisors LLC Has $142.25 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Harvest Portfolios Group Inc. Has $63.10 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Scotiabank Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $770 - Moomoo
Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B - Yahoo Finance
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? - Yahoo Finance Singapore
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price Pullback - Yahoo Finance
Regeneron Stock Tumbles 12% After Experimental Cancer Drug Misses Key Trial Goal - TIKR.com
REGN Maintained by Canaccord Genuity -- Price Target Lowered to $875 - GuruFocus
Canaccord Genuity Group Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $875.00 - MarketBeat
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $770 to $968 - Moomoo
REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations – Company AnnouncementFT.com - Financial Times
Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its Goal - Yahoo Finance
Canaccord lowers Regeneron stock price target on pipeline concerns By Investing.com - Investing.com Canada
Regeneron teams up with Parabilis to advance novel antibody Helicon - The Pharma Letter
UnitedHealth, Regeneron slip premarket; Dominion Energy, Delta Air Lines jump - Investing.com
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates - Pharmaceutical Technology
North Dakota State Investment Board Acquires Shares of 3,579 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc stock (US7739031091): strategic Parabilis deal after REGN sell-off - AD HOC NEWS
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Handelsbanken Fonder AB - MarketBeat
Citigroup downgrades Regeneron Pharmaceuticals (REGN) - MSN
Regeneron Melanoma Setback And New Collaboration Reshape Oncology Outlook - simplywall.st
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Could Cash Machine Regeneron Pharmaceuticals Stock Be Your Next Buy? - Trefis
Between Incyte and Regeneron Pharmaceuticals, Which Stock Looks Set to Break Out? - Trefis
Wolfe Research lowers Regeneron stock price target to $860 on LAG-3 miss By Investing.com - Investing.com Australia
Regeneron stock sinks after cancer trial miss prompts selloff - TechStock²
Regeneron Pharma Update Signals New Market Watchpoint - Kalkine Media
Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN) - PR Newswire
Regeneron Partners With Parabilis To Reach Undruggable Targets - Citeline News & Insights
Wolfe Research lowers Regeneron stock price target to $860 on LAG-3 miss - Investing.com Nigeria
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda - Barron's
Investigation launched into Regeneron over misleading trial optimism and stock drop - Pluang
U.S. Indexes Finished Mixed Monday As Cognizant Tech Solutions Led, Regeneron Pharmaceuticals Lagged - Barron's
Wolfe Research Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $860 - Moomoo
Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock. - Barchart.com
Why Regeneron (REGN) Shares Are Trading Lower Today - The Globe and Mail
Regeneron stock drops double digits on oncology trial failure - TradingView
REGN Downgraded by Citigroup -- Price Target Lowered to $700 - GuruFocus
REGN Maintained by Truist Securities -- Price Target Lowered to $778 - GuruFocus
Regeneron's Late-Stage Melanoma Study Misses Primary Goal - Yahoo Finance
Leerink cuts Regeneron stock rating on melanoma drug failure By Investing.com - Investing.com Australia
REGN Maintained by BMO Capital -- Price Target Lowered to $730 - GuruFocus
BMO Capital Markets Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $730.00 - MarketBeat
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 10.44% on May 18: Facts Behind the Movement - TradingKey
Nvidia Earnings Could Decide Whether the AI Trade Still Holds - Investing.com
Cantor Fitzgerald cuts Regeneron stock price target to $785 on trial failure - Investing.com UK
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down After Analyst Downgrade - MarketBeat
Regeneron Pharmaceuticals (REGN) Faces Setback in Melanoma Trial Results - GuruFocus
Regeneron Faces Nasdaq Composite Heat After Downgrade - Kalkine Media
Truist Financial Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
REGN Maintained by RBC Capital -- Price Target Lowered to $707 - GuruFocus
Regeneron: Time To Forget Fianlimab (Rating Upgrade) (NASDAQ:REGN) - Seeking Alpha
Regeneron’s fianlimab lags in melanoma, does $2.3B deal with Parabilis - BioWorld News
REGN Maintained by JP Morgan -- Price Target Lowered to $850 - GuruFocus
Regeneron Pharmaceuticals Trial Miss May Raise Broader Strategy Questions, RBC Says - Moomoo
Micron, Regeneron, UnitedHealth, Dominion Energy, Ford, Tesla, Lumentum, and More Movers - Barron's
Regeneron (REGN) Faces Setback in Melanoma Drug Trial Results - GuruFocus
Regeneron (REGN) Enters Strategic Collaboration with Parabilis M - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $850.00 Price Target at JPMorgan Chase & Co. - MarketBeat
0.81%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):